Prenetics Global Limited (PRE) announced that IM8, its wholly owned health and longevity brand, is the NBA’s Official Nutrition Partner in Australia and eight Southeast Asian markets under a multiyear collaboration. The markets are Brunei, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand and Vietnam. IM8 will conduct NBA-themed marketing campaigns and fan engagement initiatives in the region, and will host an activation at NBA House in 2027.
Prenetics CEO and IM8 co-founder Danny Yeung said the collaboration is bringing IM8 to approximately 660 million people across Australia and Southeast Asia.
Prenetics Global Ltd (PRE) director Hudson Blake Leogrande reported settlement of 2,000 vested Restricted Stock Units on October 4, 2026, with 2,000 Class A Ordinary Shares issued and delivered. The RSUs vested on June 4, 2026, under the company's 2022 Share Incentive Plan. Following the transactions, his reported direct holdings were 8,001 Class A Ordinary Shares and 16,003 Restricted Stock Units.
Prenetics Global Ltd Chief Financial Officer Hoi Chun Lo reported the disposition of 7,635 RSUs and acquisition of 7,635 Class A ordinary shares through an exercise or conversion on September 30, 2026. After the transactions, he directly held 573,648 Class A ordinary shares and 53,451 RSUs, subject to continued service and a stated vesting schedule. No Rule 10b5-1 plan is reported.
Prenetics Global Ltd (PRE) is filing a pre-effective amendment to a Form F-1 to register for resale up to 2,359,172 Class A Ordinary Shares, all issuable upon exercise of previously issued Class C “Exchange Warrants” at an exercise price of $18.00 per share. The shares may be sold from time to time by selling shareholders; Prenetics will not receive proceeds from these resales, but may receive cash if warrants are exercised for cash. As of September 8, 2026, 15,356,748 Class A Ordinary Shares were outstanding. The company describes a strategic shift toward its IM8 consumer health brand, funded in part by divestitures including a $70.0 million sale of its Insighta stake and a $41.3 million disposal of digital assets, as well as a prior $44 million equity offering and a warrant exchange that reduced potential dilution. A growth financing facility of up to $1 billion from General Catalyst’s Customer Value Fund is intended to support IM8 marketing, while extensive risk disclosures address operating in Hong Kong, potential PRC regulatory impacts, HFCAA-related delisting risk, and the Cayman holding-company structure.
Prenetics Global Ltd (PRE) filed Amendment No. 3 to its Form 20-F for 2025 to revise non-IFRS disclosures and expand explanations of its share of loss from equity-accounted investees and certain non-IFRS metrics, in response to SEC comments. The amendment does not update financial statements or other items beyond these sections.
The filing highlights Prenetics’ pivot into a consumer health and longevity platform anchored by its IM8 brand, which generated $60.1 million of revenue in its first full year and reached $120 million annualized revenue run-rate by December 2025. Total 2025 revenue from continuing operations was $92 million, up sharply from $15 million in 2024, with gross profit of $48 million and a 52.8% margin. The company still recorded a $40 million loss and an adjusted EBITDA loss of $18 million, though Q4 2025 revenue grew to $36.6 million with gross margin improving to about 59%. Prenetics executed divestitures and a $70 million Insighta stake sale, a ~$44 million equity raise, a high-participation warrant exchange, and authorized up to $40 million of share repurchases, while carrying warrant liabilities of $20.3 million at year-end 2025.
Prenetics Global Ltd (PRE) reported that director Hudson Blake Leogrande exercised vested Restricted Stock Units (RSUs) on September 4, 2026. A total of 2,000 RSUs were settled into 2,000 Class A Ordinary Shares at a conversion price of $0.0000 per share under the 2022 Share Incentive Plan. Following the transaction, he held 6,001 Class A Ordinary Shares directly and 18,003 RSUs remained outstanding, each RSU representing a contingent right to one Class A Ordinary Share. No Rule 10b5-1 trading plan is reported.
Prenetics Global Ltd (symbol: PRE) is the issuer of record for a Form 4 filing submitted to the SEC. Tat Thuan Yen reported acquisition or exercise transactions in this Form 4 filing.
Prenetics Global Ltd (PRE) reported that Tat Thuan Yen, VP, Finance of IM8 (US) LLC, received a grant of 10,730 Restricted Stock Units (RSUs) on September 3, 2026 under the company’s 2022 Share Incentive Plan. Each RSU represents one Class A Ordinary Share upon vesting and settlement, subject to continued service.
Prenetics Global Limited (NASDAQ: PRE) reported that CEO Danny Yeung and CFO Brian Rosin purchased a combined $1.0 million of ordinary shares in open-market transactions between August 20 and 25, 2026, following the release of second quarter 2026 results. Leadership has cumulatively invested about $3.75 million in company shares since November 2025, with no sales in that period.
For the second quarter of 2026, Prenetics reported $46.5 million in total revenue, up about 288% year over year, including $45.0 million from IM8, up about 359%. IM8 generated $20.9 million of revenue in July, implying an annualized run-rate of roughly $251 million, and the company recorded its first month of positive consolidated Adjusted Free Cash Flow. Prenetics raised full-year 2026 revenue guidance to $220–$230 million and introduced 2027 revenue guidance of more than $400 million.
Prenetics Global Ltd (PRE) disclosed that Brian J. Rosin, CFO of IM8 (US) LLC, purchased a total of 23,100 Class A Ordinary Shares in open-market or private transactions. He bought 18,000 shares at $21.19 per share on August 24, 2026 and 5,100 shares at $22.80 per share on August 25, 2026. The Rule 10b5-1 checkbox was not marked, indicating these trades were not reported as made under a trading plan.
Prenetics Global Ltd (PRE) reports the initial equity holdings of director Caroline S. Levy. She holds 7,595 Restricted Stock Units (RSUs), each representing a contingent right to receive one Class A ordinary share. These RSUs vest on August 17, 2027, subject to continued service, and expire on August 17, 2033.